ES
ATNM icon

Equitec Specialists’s Actinium Pharmaceuticals ATNM Stock Holding History

Equitec Specialists’s Portfolio ATNM Stock Details ATNM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		– Sell
-727
Closed -$54K – 94
2015
Q1 		$54K Buy
+727
New +$86.5K 0.02% 79

Other funds holding ATNM

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
TCIM
TIAA CREF Investment Management New York $141B AUM 14.18% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $5.69B AUM 60.64% 1-Year Est. Return
DCM
DAFNA Capital Management Los Angeles, California $524M AUM 164.42% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Equitec Specialists's ATNM Position: Q2 2015 in Review

Equitec Specialists sold out of Actinium Pharmaceuticals (ATNM) in Q2 2015, closing a stake of 727 shares — an estimated $54K sold.

Equitec Specialists first reported a position in ATNM in Q1 2015 and held it in 1 quarter. The position peaked at $54K in Q1 2015. 39 funds tracked by Wall St. Rank hold ATNM as of Q2 2015.

  • Equitec Specialists reported no remaining Actinium Pharmaceuticals position as of Q2 2015 after selling out during the quarter.
  • Equitec Specialists sold 727 Actinium Pharmaceuticals shares in Q2 2015, an estimated $54K.
  • Equitec Specialists first reported a position in Actinium Pharmaceuticals in Q1 2015 and held it in 1 quarter.
  • Equitec Specialists's Actinium Pharmaceuticals position peaked at $54K in Q1 2015.
  • 39 funds tracked by Wall St. Rank held Actinium Pharmaceuticals as of Q2 2015.

Based on Equitec Specialists's 13F filing for Q2 2015, filed 5 Aug 2015.